Does dexamethasone suppress the Mazzotti reaction in patients with onchocerciasis?
- PMID: 2896449
Does dexamethasone suppress the Mazzotti reaction in patients with onchocerciasis?
Abstract
The Mazzotti reaction is a frequent complication in patients with onchocerciasis being treated with diethylcarbamazine (DEC); and more severe manifestations of this reaction may be unacceptable in many patients. It has recently been demonstrated that prednisone modifies the severity of this reaction and reduces the microfilaricidal activity of DEC. A clinical trial was performed at the National Leprosy Training Center in Wau, Sudan, to evaluate the clinical and histologic effect of the use of corticosteroids in patients receiving DEC. Administration of a low dose of dexamethasone (3 mg/day), begun after onset of the Mazzotti reaction, modifies the progression of the Mazzotti reaction without interfering with the microfilaricidal efficacy of DEC. Pretreatment with low-dose dexamethasone--prior to beginning DEC therapy--prevents the development of the Mazzotti reaction and greatly reduces the microfilaricidal activity. Administration of diphenhydramine, after onset of the Mazzotti reaction, has no effect on the course and intensity of the Mazzotti reaction nor on microfilaricidal activity. We recommend that low-dose corticosteroids be administered in conjunction with DEC--after onset of the Mazzotti reaction--and that they be tapered rapidly.
Similar articles
-
[Cutaneous changes induced by a dose of DEC in rodents with skin microfilaria: relevance of these phenomena for understanding the Mazzotti reaction and the pathogenesis of human onchocerciasis].C R Acad Sci III. 1987;304(6):133-8. C R Acad Sci III. 1987. PMID: 3103881 French.
-
Leprosy, onchocerciasis, diethylcarbamazine and the Mazzotti reaction.Lepr Rev. 1982 Dec;53(4):317-8. Lepr Rev. 1982. PMID: 7154815 No abstract available.
-
Eosinophil degranulation. An immunologic determinant in the pathogenesis of the Mazzotti reaction in human onchocerciasis.J Immunol. 1990 May 15;144(10):3961-9. J Immunol. 1990. PMID: 2332637
-
Ivermectin--clinical trials and treatment schedules in onchocerciasis.Acta Leiden. 1990;59(1-2):169-75. Acta Leiden. 1990. PMID: 2198749 Review.
-
[Short review of pathophysiology and therapeutic possibilities in onchocerciasis with reference to a case report].Wien Klin Wochenschr. 1994;106(11):354-8. Wien Klin Wochenschr. 1994. PMID: 8053203 Review. German.
Cited by
-
Infection-associated Immune Perturbations Resolve 1 Year Following Treatment for Loa loa.Clin Infect Dis. 2021 Mar 1;72(5):789-796. doi: 10.1093/cid/ciaa137. Clin Infect Dis. 2021. PMID: 32055862 Free PMC article.
-
A Randomized, Placebo-controlled, Double-blind Pilot Study of Single-dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa loa Infection.Clin Infect Dis. 2021 Oct 5;73(7):e1624-e1631. doi: 10.1093/cid/ciaa1365. Clin Infect Dis. 2021. PMID: 32910141 Free PMC article. Clinical Trial.
-
Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon.Filaria J. 2003 Oct 24;2 Suppl 1(Suppl 1):S4. doi: 10.1186/1475-2883-2-S1-S4. Filaria J. 2003. PMID: 14975061 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials